Last reviewed · How we verify
TLC590
TLC590 is a liposomal formulation designed to deliver its active pharmaceutical ingredient with improved pharmacokinetics and reduced systemic toxicity.
At a glance
| Generic name | TLC590 |
|---|---|
| Also known as | TLC590 (Ropivacaine Liposome Injectable Suspension), TLC590 (Ropivacaine Extended-Release Injectable Suspension), intestigational drug |
| Sponsor | Taiwan Liposome Company |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a liposomal drug product developed by Taiwan Liposome Company, TLC590 encapsulates its active agent within lipid vesicles to enhance drug stability, prolong circulation time, and enable preferential accumulation at target tissues. This formulation approach typically reduces off-target toxicity while improving therapeutic efficacy compared to conventional formulations.
Approved indications
Common side effects
Key clinical trials
- A Study on TLC590 for Managing Postsurgical Pain (PHASE2)
- A Study of TLC590 for Postsurgical Pain Following Bunionectomy (PHASE3)
- A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee (PHASE2)
- Phase 2/3 Study of TLC590 for Postsurgical Pain Management (PHASE2, PHASE3)
- Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management (PHASE1, PHASE2)
- A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLC590 CI brief — competitive landscape report
- TLC590 updates RSS · CI watch RSS
- Taiwan Liposome Company portfolio CI